Syndrome News and Research

RSS
Researchers develop artificial adrenal system in animal model

Researchers develop artificial adrenal system in animal model

Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis provides overview of standalone global pharmaceutical development pipeline

Training modules for emergency department staff to treat infectious disease patients available on CDC's website

Training modules for emergency department staff to treat infectious disease patients available on CDC's website

Corticosteroids decrease treatment failure among patients with community-acquired pneumonia

Corticosteroids decrease treatment failure among patients with community-acquired pneumonia

Trinity scientists reveal new marvel molecule that can block key process in inflammatory diseases

Trinity scientists reveal new marvel molecule that can block key process in inflammatory diseases

Fusobacterium necrophorum often causes severe sore throats in young adults

Fusobacterium necrophorum often causes severe sore throats in young adults

FOI Request by Bowel Cancer UK highlights big variation in tests for lynch syndrome

FOI Request by Bowel Cancer UK highlights big variation in tests for lynch syndrome

Harmless plant extract can help treat Cushing Disease

Harmless plant extract can help treat Cushing Disease

Eight clinical researchers selected as finalists for Outstanding Investigator Award at Cardiology 2015

Eight clinical researchers selected as finalists for Outstanding Investigator Award at Cardiology 2015

Scientists find seven new genes that can cause X-linked intellectual disability

Scientists find seven new genes that can cause X-linked intellectual disability

New antibody shows promise in increasing survival for patients suffering from influenza, pneumonia

New antibody shows promise in increasing survival for patients suffering from influenza, pneumonia

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Declarative memory helps individuals with neurodevelopmental disorders compensate for dysfunction

Declarative memory helps individuals with neurodevelopmental disorders compensate for dysfunction

New computer-simulated prescribing strategies for glasses may help Down syndrome patients see better

New computer-simulated prescribing strategies for glasses may help Down syndrome patients see better

Experts gather at Cardiology 2015 conference to discuss challenges in treating congenital heart disease

Experts gather at Cardiology 2015 conference to discuss challenges in treating congenital heart disease

Opioid withdrawal in Ontario newborns increases 15-fold

Opioid withdrawal in Ontario newborns increases 15-fold

Experts to discuss challenges in CHD treatments at pediatric cardiology conference

Experts to discuss challenges in CHD treatments at pediatric cardiology conference

Cumberland initiates clinical development of Boxaban (ifetroban) oral capsule for AERD treatment

Cumberland initiates clinical development of Boxaban (ifetroban) oral capsule for AERD treatment

First human clinical study of ChromaDex's NIAGEN nicotinamide riboside meets primary endpoint

First human clinical study of ChromaDex's NIAGEN nicotinamide riboside meets primary endpoint

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.